Health Condition 1: M638- Disorders of muscle in diseases classified elsewhere
Conditions
Interventions
Intervention1: AFO-202: 1g of AFO-202 Beta Glucan daily (1 g sachet with any one meal)
Intervention2: AFO-202 and N-163: 1g of AFO-202 Beta Glucan daily (1 g sachet with any one meal)
1 sachet of N-
Sponsors
NichiIn Biosciences Pvt Ltd
GN Corporation Co Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subject who diagnosed with DMD 2. Aged from 6-18 3. Patients who are to participate in the study with a written inform consent form.
Exclusion criteria
Exclusion criteria: Subjects who are not a part of any clinical studies prior to 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of changes in the levels of IL-6 and Myoglobin urea from the baseline.Timepoint: Day 45±1 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Measurement of the levels of CK, Titin, TNF, Haptoglobin, Dystrophin level, LFT,CBC,Cystatin C 2. Immunological Parameters: IL-13,CD-40,ESR Timepoint: Day 1, Day21 ± 1, Day 45±1 and Monitoring Adverse events each visits | — |
Countries
India
Contacts
Public ContactDr S R Tiruvalavan
Kenmax Medical Service Private Limited
Outcome results
None listed